obesity pill

Structure Therapeutics (NASDAQ: GPCR) Stock Explodes on Obesity Pill Data and $500M Offering: Latest News and Forecasts as of December 9, 2025

Snapshot: Where Structure Therapeutics Stock Stands Today Structure Therapeutics Inc. (NASDAQ: GPCR) has suddenly moved from niche obesity biotech to front‑page market story. As of December 9, 2025, GPCR is trading around $69.98, up roughly 102% in a single session

9 December 2025

Structure Therapeutics (GPCR) Stock Soars on Obesity Pill Data: Latest News, Analyst Forecasts and 2026 Outlook (December 8, 2025)

Structure Therapeutics Inc. (NASDAQ: GPCR) just turned a long‑anticipated clinical readout into a full‑blown stock market event. On Monday, December 8, 2025, the company released positive topline data from its ACCESS program for aleniglipron (GSBR‑1290), a once‑daily oral GLP‑1 receptor

8 December 2025

Analyst Insights · Biotechnology · Investment News · Pharmaceutical Industry · Stock Market

Obesity Pill Breakthrough, Gene Therapy Triumph & Billion-Dollar Psychedelic Bet – Global Biotech & Health Highlights (Aug 26–27, 2025)

Key Facts Sources

27 August 2025

Biotech · Gene Therapy · Health · NASDAQ:PGEN · NYSE:ABBV · NYSE:LLY · Obesity · Psychedelics